Takeda’s oral TYK2 blocker outperforms Sotyktu in PsA trial

Based on this data and data from two other Phase III trials, Takeda will file for the approval of zasocitinib in PsA. Based on this data and data from two other Phase III trials, Takeda will file for the approval of zasocitinib in PsA. Takeda is hoping to get a grasp on some of the PsA market which GlobalData forecasts will be worth $11.56bn in 2030. Credit: Michael Vi / Shutterstock.com Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor has outperformed Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis (PsO). In the Phase III LATITUDE Atlas head-to-head…

Source: Clinical Trials Arena